AnaptysBio (ANAB) Competitors

AnaptysBio (NASDAQ:ANAB) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation, analyst recommendations and community ranking.

Do insiders and institutionals believe in ANAB or GHRS?

56.9% of GH Research shares are held by institutional investors. 35.5% of AnaptysBio shares are held by insiders. Comparatively, 41.6% of GH Research shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in ANAB or GHRS?

AnaptysBio received 333 more outperform votes than GH Research when rated by MarketBeat users. Likewise, 65.54% of users gave AnaptysBio an outperform vote while only 65.38% of users gave GH Research an outperform vote.

Company	Underperform	Outperform
AnaptysBio	Outperform Votes 350 65.54%	Underperform Votes 184 34.46%
GH Research	Outperform Votes 17 65.38%	Underperform Votes 9 34.62%

Does the media favor ANAB or GHRS?

In the previous week, AnaptysBio had 11 more articles in the media than GH Research. MarketBeat recorded 16 mentions for AnaptysBio and 5 mentions for GH Research. AnaptysBio's average media sentiment score of 0.72 beat GH Research's score of 0.12 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	5 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GH Research	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts recommend ANAB or GHRS?

AnaptysBio presently has a consensus price target of $46.22, suggesting a potential upside of 133.09%. GH Research has a consensus price target of $39.50, suggesting a potential upside of 252.99%. Given GH Research's stronger consensus rating and higher possible upside, analysts clearly believe GH Research is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
GH Research	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is ANAB or GHRS more profitable?

GH Research has a net margin of 0.00% compared to AnaptysBio's net margin of -953.66%. GH Research's return on equity of -15.48% beat AnaptysBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-953.66%	-119.42%	-32.58%
GH Research	N/A	-15.48%	-15.01%

Which has more risk & volatility, ANAB or GHRS?

AnaptysBio has a beta of -0.3, indicating that its stock price is 130% less volatile than the S&P 500. Comparatively, GH Research has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.

Which has higher valuation and earnings, ANAB or GHRS?

GH Research has lower revenue, but higher earnings than AnaptysBio. GH Research is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$17.16M	30.92	-$163.62M	-$6.08	-3.26
GH Research	N/A	N/A	-$35.59M	-$0.68	-16.46

Summary

GH Research beats AnaptysBio on 10 of the 17 factors compared between the two stocks.